Olaf B. Paulson from Københavns Universitet - University of Copenhagen and Rigshospitalet highlights, in this MEDtalk, some clinical discoveries within the history of Danish neuroscience. 🔗 See more from EAN 2024 here: https://lnkd.in/dV62Xfaq #EAN24 #Neuroscience
Neurologi DK
Bog- og tidsskriftsforlag
Virum, Hovedstaden 186 følgere
Få seneste forskningsnyt inden for neurologi
Om os
Gå ikke glip af det nyeste fra neurologi. Læs nye artikler skrevet af specialister, se MEDtalks hvor der bl.a. præsenteres den nyeste forskning, tag faglige test og læs magasiner inden for dit fagområde.
- Websted
-
https://bpno.dk/specialer/neurologi/
Eksternt link til Neurologi DK
- Branche
- Bog- og tidsskriftsforlag
- Virksomhedsstørrelse
- 11-50 medarbejdere
- Hovedkvarter
- Virum, Hovedstaden
- Grundlagt
- 2019
Opdateringer
-
At EAN 2024, Kristian Steen Frederiksen from the Danish Dementia Research Center chaired a session that broadly focused on the ongoing steps forward in understanding the pathophysiology and disease mechanisms of Alzheimer’s disease. In this MEDtalk, he briefly discusses some of the session’s highlights. 📎 See more from EAN 2024 here: https://lnkd.in/dV62Xfaq #Alzheimers #AntiAmyloid #Treatment
New Treatments for Alzheimer's Disease with Anti-Amyloid Antibodies
https://bpno.dk
-
Darrell Lewis from Duke University Medical Center presents: The FEBSTAT study links prolonged infantile febrile seizures to hippocampal sclerosis and mesial temporal lobe epilepsy, highlighting the prognostic value of MRI monitoring. #Seizures #Sclerosis #Epilepsy
Sequelae of Febrile Status Epilepticus – Results from the FEBSTAT Study
https://bpno.dk
-
Wanqing Wu, a PhD student from Karolinska Institute, discusses the Swedish Myasthenia Gravis (MG) Registry at the European Academy of Neurology 2024 Congress. Initiated in 2011, the registry includes over 1,700 MG patients, representing about 60% of Sweden's MG population. Preliminary findings include the average age of MG onset at 50 years, common antibody presence, and significant use of rituximab. 🔗See more from EAN 2024: https://lnkd.in/dV62Xfaq #EAN24 #MyastheniaGravis
Preliminary Findings from the Swedish Myasthenia Gravis Registry
https://bpno.dk
-
Watch Michael Schöll, professor at the Göteborgs universitet and principal research fellow at @University College London, discuss blood-based biomarkers for early Alzheimer’s diagnosis presented at EAN 2024. He outlines the REAL AD study, which aims to validate a realistic screening approach for early Alzheimer’s using digital and blood-based biomarkers and its potential to improve Alzheimer’s diagnostics in primary care. #EAN24 #Alzheimers #Neurology
Blood-Based Biomarkers for Early Alzheimer's Disease Diagnosis
https://bpno.dk
-
Sanna-Kaisa Herukka, from the University of Eastern Finland, presents therapies beyond amyloid in the treatment of Alzheimer’s disease in this MEDtalk. At EAN 2024, she discussed potential tau therapies, drugs for neuropsychiatric symptoms, and the promising results of GLP-1 mimics, which have already shown clinically significant improvements in Parkinson’s disease and may also be effective in Alzheimer’s disease. #EAN24 #Alzheimers #Neurology
Anti-Amyloid Antibodies in Alzheimer's Disease: New Treatments on the Horizon
https://bpno.dk
-
Palliative care for epilepsy should not be seen as separate from active care but rather as a complementary approach throughout the disease progression, according to Reetta Kalviainenäinen, from the Epilepsy Centre at Kuopio University Hospital (KUH) - Kuopion yliopistollinen sairaala (KYS), who spoke at the European Academy of Neurology 2024 Congress about the need to integrate palliative care early in the treatment of severe epilepsies. She also highlighted the importance of effective seizure management in palliative care and the potential of remote care. 🔗Follow along as we cover EAN 2024: https://lnkd.in/dV62Xfaq #EAN24 #Epilepsy
Palliative Care of Severe Epilepsy
https://bpno.dk
-
In this MEDtalk from the European Academy of Neurology 2024 Congress, Ludmilla Morozova-Roche, a professor at Umeå University in Sweden, discusses her research on amyloid neuro-inflammatory cascades in neurodegenerative diseases, including Alzheimer's, Parkinson's, and traumatic brain injury. She highlights the role of the pro-inflammatory protein S100A9 in these conditions and its potential as a therapeutic target and biomarker. 🔗See more of our coverage of the EAN 2024 Congress: https://lnkd.in/dV62Xfaq #EAN24 #Alzheimers #Parkinson
The Role of Pro-Inflammatory S100A9 Protein in Amyloid-Neuroinflammatory Cascade in Neurodegenerative Diseases
https://bpno.dk
-
Today there are no standardised treatments to deprescribe inappropriate z-hypnotic use in older. Tahreem Ghazal Siddiqui, Akershus University Hospital, Oslo, Norway, and her groupe are working for to development a standardised trategy for this. In this MEDtalk she describe a project on the development process of a brief intervention for deprescribing inappropriate z-hypnotic use in older adults. 🔗See more from the European Academy of Neurology 2024 Congress here: https://lnkd.in/dV62Xfaq #EAN24 #Neurology
Dose reduction or stopping inappropriate z-hypnotic use in older adults
https://bpno.dk
-
This study aimed to improve the diagnostic accuracy of idiopathic intracranial hypertension (IIH) and concluded that eye exams, especially optic nerve evaluations, significantly enhance diagnosis, recommending fundus photography, transorbital ultrasonography, and collaboration with neuro-ophthalmologists. Implementing national guidelines markedly improved patient care. Nadja Skadkaer Hansen from Rigshospitalet elaborates in this MEDtalk from the European Academy of Neurology 2024 Congress. 🔗Follow along for more from EAN 2024: https://lnkd.in/dV62Xfaq #EAN24 #Hypertension
Diagnostic Process, Misdiagnosis, and Bias in Suspected Idiopathic Intracranial Hypertension
https://bpno.dk